{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:32:15Z","timestamp":1718757135933},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1705","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved rezafungin (Rezzayo \u2013 Cidara\/Melinta), an intravenous echinocandin antifungal, for once-weekly treatment of candidemia and invasive candidiasis (IC) in adults with limited or no alternative options. It is the first new drug to become available in the US in more than 15 years for treatment of systemic Candida infections.<\/jats:p>","DOI":"10.58347\/tml.2024.1705d","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T17:05:12Z","timestamp":1718730312000},"page":"101-104","source":"Crossref","is-referenced-by-count":0,"title":["Rezafungin (Rezzayo) for Invasive Candida Infections"],"prefix":"10.58347","volume":"66","member":"37151","published-online":{"date-parts":[[2024,6,24]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T17:05:12Z","timestamp":1718730312000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1705d"}},"subtitle":[],"editor":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":0,"journal-issue":{"issue":"1705","published-online":{"date-parts":[[2024,6,24]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2024.1705d","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,24]]}}}